<?xml version="1.0" encoding="UTF-8"?>
<included>
<!-- start of a new study -->
<study>
<citation year="2009" pmid="19297565" trialregistration="NCT00002540" journal_abbrev="N Engl J Med">Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial</citation>
 <design>Randomized controlled trial</design>
 <patients total="76,693">
 <description>Males ages 55 to 74</description>
 <bullet>Mean age not stated, but between 60 and 64 years</bullet>
 </patients>
 <intervention>Serial testing of levels of prostate-specific antigen
 <bullet>Every one year</bullet>
 <bullet>Duration of screening 6 years</bullet>
 <bullet>Mean tests performed: 5.1 tests per male</bullet>
 <bullet>PSA level defined as abnormal: 4 ng per mL</bullet>
 </intervention>
 <comparison>Usual care
 <bullet>Contamination rate: 52% of controls</bullet>
 <bullet>Mean tests performed: 2.7 tests per male (reported)</bullet>
</comparison>
<outcome>
 <bullet type='primary' url=''>Death from prostate cancer</bullet>
 </outcome>
</study>
<!-- start of a new study -->
<study>
<citation year="2009" pmid="19297566" trialregistration="ISRCTN49127736" journal_abbrev="N Engl J Med" totalsubjects="162,243" >European Randomized Study of Screening for Prostate Cancer (ERSPC)</citation>
 <design>Randomized controlled trial</design>
 <patients total="162,243">
 <description>Males ages 50 to 74</description>
 <bullet>Mean age 61 years</bullet>
 </patients>
 <intervention>Serial testing of levels of prostate-specific antigen
 <bullet>Every 4 years</bullet>
 <bullet>Duration of screening 13 years</bullet>
 <bullet>Mean tests performed: 1.7 tests per male</bullet>
 <bullet>PSA level defined as abnormal: 3 ng per mL</bullet>
 </intervention>
 <comparison>Usual care
 <bullet>Contamination rate: 31% of controls</bullet>
 <bullet>Mean tests performed: not reported</bullet>
</comparison>
<outcome>
 <bullet type='primary' url=''>Death from prostate cancer</bullet>
 </outcome>
</study>
<!-- start of a new study -->
<study>
<citation year="2010" pmid="20598634" trialregistration="ISRCTN54449243" journal_abbrev="Lancet Oncol" totalsubjects="8057" >Goteborg trial</citation>
 <design>Randomized controlled trial</design>
 <patients total="8057">
 <description>Males ages 50 to 64</description>
 <bullet>Mean age 56 years</bullet>
 <bullet>Cohort born in 1930-1939 also included in ERSPC</bullet>
 <bullet>Cohort born in 1940-1944 are not included in ERSPC</bullet>
 </patients>
 <intervention>Serial testing of levels of prostate-specific antigen
 <bullet>Every 2 years</bullet>
 <bullet>Duration of screening 14 years</bullet>
 <bullet>Mean tests performed: 3.9 tests per male</bullet>
 <bullet>PSA level defined as abnormal: 3 ng per mL</bullet>
 </intervention>
 <comparison>Usual care
 <bullet>Contamination rate: 31% of controls (presumed based on rate in ERSPC)</bullet>
 <bullet>Mean tests performed: not reported</bullet>
</comparison>
<outcome>
 <bullet type='primary' url=''>Death from prostate cancer</bullet>
 </outcome>
</study>
<study>
<citation year="2004" pmid="15042607" trialregistration="" journal_abbrev="Prostate" totalsubjects="46486" >Quebec (Labie)</citation>
 <design>Randomized controlled trial</design>
 <patients total="464860">
 <description>Males ages __ - __</description>
 <bullet>Mean age __ years</bullet>
 </patients>
 <intervention>Serial testing of levels of prostate-specific antigen
 <bullet>Every _ years</bullet>
 <bullet>Duration of screening __ years</bullet>
 <bullet>Mean tests performed: __ tests per male</bullet>
 <bullet>PSA level defined as abnormal: _ ng per mL</bullet>
 </intervention>
 <comparison>Usual care
 <bullet>Contamination rate: __of controls ()</bullet>
 <bullet>Mean tests performed: __ ()</bullet>
</comparison>
<outcome>
 <bullet type='primary' url=''>Death from prostate cancer</bullet>
 </outcome>
</study>
<study>
<citation year="2009" pmid="19233435" trialregistration="" journal_abbrev="J Urol" totalsubjects="27146" >Stockholm (Kjellman)</citation>
 <design>Randomized controlled trial</design>
 <patients total="27146">
 <description>Males ages 55 - 70</description>
 <bullet>Mean age 62 years</bullet>
 </patients>
 <intervention>**Single** testing of level of prostate-specific antigen
 <bullet>**One time**</bullet>
 <bullet>Duration of screening 1 years</bullet>
 <bullet>Mean tests performed: 0.74 tests per male</bullet>
 <bullet>PSA level defined as abnormal: 7 ng per mL</bullet>
 </intervention>
 <comparison>Usual care
 <bullet>Contamination rate: not reported</bullet>
 <bullet>Mean tests performed: not reported</bullet>
</comparison>
<outcome>
 <bullet type='primary' url=''>Death from prostate cancer</bullet>
 </outcome>
</study>
<study>
<citation year="2011" pmid="21454449" trialregistration="ISRCTN06342431" journal_abbrev="BMJ" totalsubjects="9026" >Norrkoping (Sandblom)</citation>
 <design>Randomized controlled trial</design>
 <patients total="9026">
 <description>Males ages __ - __</description>
 <bullet>Mean age __ years</bullet>
 </patients>
 <intervention>Serial testing of levels of prostate-specific antigen
 <bullet>Every _ years</bullet>
 <bullet>Duration of screening __ years</bullet>
 <bullet>Mean tests performed: __ tests per male</bullet>
 <bullet>PSA level defined as abnormal: _ ng per mL</bullet>
 </intervention>
 <comparison>Usual care
 <bullet>Contamination rate: __of controls ()</bullet>
 <bullet>Mean tests performed: __ ()</bullet>
</comparison>
<outcome>
 <bullet type='primary' url=''>Death from prostate cancer</bullet>
 </outcome>
</study>
<!-- Leave this bottom line -->
</included>
